Routine equity plan adoption with no immediate trading implications. Monitor future Form 4 filings and 10-Q/20-F for actual grant activity under the new plan, which would indicate potential dilution. The company's $210.8M cash position (per prior 20-F) suggests sufficient runway, making near-term equity issuance less likely.
Price Chart
Executive Summary
NovaBridge Biosciences adopted a new 2026 Omnibus Share Incentive Plan, authorizing up to 11,960,000 ordinary shares (5,200,000 ADSs) for equity awards, with an annual evergreen increase of up to 3% of outstanding shares. The plan replaces five predecessor plans and is a routine governance action to maintain employee incentive capacity.
Key Facts
- Board adopted 2026 Omnibus Share Incentive Plan effective July 13, 2026, with a 10-year term
- Maximum initial authorization: 11,960,000 ordinary shares (5,200,000 ADSs)
- Annual evergreen increase on Jan 1 from 2027-2036: lesser of 3% of outstanding shares or Board-determined amount
- Replaces five predecessor plans (2020, 2021, 2022, 2024, 2025); outstanding awards under prior plans remain governed by their original terms
- Plan allows for options, SARs, restricted shares, share units, cash-based and share-based awards
Financial Impact
No immediate financial impact; potential future dilution from equity grants under the plan, but no grants disclosed in this filing
Risk Factors
- Potential future dilution from equity grants to employees and directors
- Annual evergreen provision could increase share count by up to 3% per year without shareholder vote
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-306688 |
| Document: 6-k_-_2026_esop.htm | 0001193125-26-306688 |
| Document: 0001193125-26-306688-index-headers.html | 0001193125-26-306688 |
| Document: 0001193125-26-306688-index.html | 0001193125-26-306688 |
| Document: 0001193125-26-306688.txt | 0001193125-26-306688 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.49 | awaiting T+5 | — | $1.25 (−15.77%) |
Oct 25, 2026 2d ago | Press Release | $1.42 | awaiting T+5 | — | $1.25 (−11.62%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.25 (−8.39%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.25 (−2.71%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.25 (−34.29%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.25 (−29.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers